Spondyloarthropathies News

Artificial neural networks can assess and detect radiographic sacroiliitis, helping physicians to diagnose and classify axial spondyloarthritis, according to data presented at the American College of Rheumatology 2020 Annual Meeting.

Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.

How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Hear what a rheumatologist should know about IBD!

At least 65% of rheumatologists at Veterans Affairs facilities view telemedicine as appropriate for established patients with gout, stable rheumatoid arthritis, osteoarthritis, stable spondyloarthritis and other diseases, researchers noted.

Short interruptions in face-to-face rheumatology visits due to COVID-19 considerations resulted in no major negative effects for patients with inflammatory arthritis, according to findings published in Annals of the Rheumatic Diseases.

The percentage of adult arthritis visits to office-based physicians increased significantly during 2006-2015, with the percentage of visits where opioids were prescribed also increasing during that time, according to data.

Latent tuberculosis infection was an uncommon adverse event after treatment with secukinumab for chronic systemic inflammatory conditions, according to a study published in JAMA Dermatology.

Strong data for two interleukin-17 inhibitors have given a lift to clinicians treating the spondyloarthropathies, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

TNF inhibitors and methotrexate produced similar reductions in HbA1c among patients with psoriatic arthritis, rheumatoid arthritis or ankylosing spondylitis who also have diabetes, according to data published in BMC Rheumatology.

Pain and fatigue levels remain high among patients with ankylosing spondylitis despite apparent disease control with biologic therapies, such as TNF inhibitors, according to a global survey published in the Journal of Clinical Rheumatology.